Semaglutide Week 43: What to Expect at This Stage

Expected Weight Loss at Week 43

Clinical data and patient experience suggest that by week 43, cumulative weight loss on semaglutide 2.4 mg typically falls in the range of 15 to 17 percent of starting body weight. The rate of weekly weight loss at this stage is generally between 0.3 and 0.8 pounds per week, which is notably slower than the 1 to 2 pounds per week that many patients experienced during the first few months of treatment.

This slower pace is physiologically normal and expected. As body weight decreases, the body's energy expenditure also decreases, narrowing the caloric deficit that drives weight loss. Additionally, metabolic adaptation means the body becomes more efficient at using fewer calories. These are not signs of treatment failure but rather normal biological responses to sustained weight loss.

For a detailed understanding of how semaglutide dosing affects weight loss patterns, including why the maximum dose of 2.4 mg is typically maintained through this stage of treatment, consult our comprehensive dosage guide.

Body Composition Changes at Week 43

By week 43, body composition has typically stabilized at a significantly improved level compared to baseline. Patients who have incorporated strength training throughout treatment often show the most favorable body composition profiles, with preserved lean muscle mass and substantially reduced body fat percentage. Regular body composition assessments, rather than relying solely on scale weight, provide the most accurate picture of treatment success at this stage.

Research published alongside the STEP trials indicates that approximately 40 percent of weight lost on semaglutide is fat-free mass, with the remaining 60 percent being fat mass. Patients who engage in regular resistance training may improve this ratio, losing a higher proportion of fat while preserving more lean tissue. This is why exercise guidance is an essential complement to semaglutide therapy.

Side Effects at Week 43

Side effects at week 43 are generally negligible for the vast majority of patients. The body has fully adapted to semaglutide at this point, and the medication's effects on appetite and satiety have become the normal baseline experience. Patients who do experience any residual effects typically describe them as mild and predictable, occurring mainly in response to specific dietary triggers that they have learned to manage.

If you are experiencing persistent or new side effects at week 43, it is important to discuss these with your healthcare provider. While rare at this stage, new symptoms may indicate the need for clinical evaluation or dose adjustment. For a comprehensive overview of potential effects at any treatment stage, see our guide to semaglutide side effects.

Psychological Adjustment and Mindset

The psychological adjustment at week 43 often involves coming to terms with a new self-image and lifestyle. Many patients report that they have fully internalized their new eating patterns and physical activity habits. The challenge at this stage is sometimes the opposite of early treatment concerns, as patients may need to resist the urge to become complacent or to assume that the work is done simply because the scale has stabilized.

Many patients find it helpful to focus on non-scale victories at this stage: improved energy levels, better sleep quality, reduced joint pain, enhanced mobility, improved lab values, and greater confidence in social situations. These outcomes are often more meaningful indicators of treatment success than the number on the scale, particularly at week 43 when weight loss may be approaching its natural plateau.

Long-Term Health Benefits

The cumulative health benefits at week 43 are substantial. Patients typically show significant improvements in HbA1c, blood pressure, triglycerides, and LDL cholesterol compared to their pre-treatment baseline. Research from the SELECT trial has demonstrated cardiovascular benefits of semaglutide that persist with continued use, reinforcing the value of ongoing treatment beyond weight management alone.

Patients interested in understanding the full spectrum of GLP-1 medication benefits should review our complete GLP-1 guide, which covers the cardiovascular, metabolic, and emerging therapeutic applications of this medication class. Additionally, comparing semaglutide with tirzepatide may be relevant for patients considering alternative or complementary treatment options.

Maintenance Strategies for Week 43 and Beyond

At week 43, maintenance is the primary focus. Patients should be having detailed conversations with their provider about the long-term treatment plan. Current evidence suggests that many patients benefit from continued semaglutide use to maintain weight loss, as discontinuation studies have shown significant weight regain after stopping the medication. Understanding this reality helps patients make informed decisions about their ongoing treatment.

Learn more about how Trimi's medical team supports patients through every phase of treatment, from initial dose escalation through long-term maintenance. Our transparent pricing ensures that ongoing treatment remains accessible as your needs evolve.

When to Talk to Your Provider

While week 43 is generally a stable point in semaglutide treatment, there are situations that warrant a conversation with your healthcare provider. Contact your medical team if you experience any new or worsening side effects, if your weight loss has completely stalled for more than 4 to 6 weeks, if you are considering stopping or changing your medication, or if you have questions about transitioning your treatment plan.